NCT02805660 is a Phase 1, PHASE2 clinical trial of Mocetinostat - 50 mg in Advanced Cancer, sponsored by Mirati Therapeutics Inc..

Who is sponsoring NCT02805660?

NCT02805660 is sponsored by Mirati Therapeutics Inc..

What drugs are being tested in NCT02805660?

Interventions in NCT02805660: Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg, Mocetinostat - Recommended Phase 2 Dose (70 mg), Durvalumab - 1500 mg.

What condition does NCT02805660 study?

NCT02805660 studies Advanced Cancer.

Is NCT02805660 still recruiting?

NCT02805660 is currently terminated. Last updated 6 April 2021.

Are results published for NCT02805660?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-04-06 · How we verify

NCT02805660

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Terminated Phase 1, PHASE2 Results posted Last updated 6 April 2021

What this trial tests

Phase 1, PHASE2 trial testing Mocetinostat - 50 mg in Advanced Cancer in 83 participants. Terminated before completion.

Timeline

1 June 2016

Primary endpoint
14 December 2019

20 December 2019

Quick facts

Lead sponsor	Mirati Therapeutics Inc.
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	83
Start date	1 June 2016
Primary completion	14 December 2019
Estimated completion	20 December 2019
Sites	15 locations across United States

Drugs / interventions tested

Mocetinostat - 50 mg — full drug profile →
Mocetinostat - 70 mg — full drug profile →
Mocetinostat - 90 mg — full drug profile →
Mocetinostat - Recommended Phase 2 Dose (70 mg) — full drug profile →
Durvalumab - 1500 mg

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

Mirati Therapeutics Inc. — full company profile →

Who can join

18 and older, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During the First 28-day Cycle of Combination Treatment In Phase 1 Primary · 28 days

Toxicities were graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Any of the following events considered to be causally related to treatment with mocetinostat in combination with durvalumab that occurred during Phase 1 were considered a DLT: * Any Grade 4 immune-related adverse event (irAE) * Grade 3 or greater colitis * Grade 3 or greater noninfectious pneumonitis * Grade 2 pneumonitis that did not resolve to ≤ Grade 1 within 3 days of the initiation of maximal supportive care * Grade 3 irAE (excluding colitis or pneumonitis) t

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	0
Phase 1: Dose Escalation - 70 mg	0
Phase 1: Dose Escalation - 90 mg	0

Objective Response Rate (ORR) Primary · Up to approximately 10 months

Objective Response Rate (ORR) was defined as the number of participants documented to have a confirmed Complete Response (CR) or Partial Response (PR). Complete Response was defined as the complete disappearance of all target lesions with the exception of nodal disease. Partial Response was defined at least a 30% decrease in the sum of diameters of target measurable lesions. Responses were determined by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Participants without response data were counted as non-responders. Inferential statistical analyses were conduct

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	0	0.0 – 52.2
Phase 1: Dose Escalation - 70 mg	0	0.0 – 60.2
Phase 1: Dose Escalation - 90 mg	0	0.0 – 33.6
Phase 2: Combination Regimen - Cohort 1	6.7	0.2 – 31.9
Phase 2: Combination Regimen - Cohort 2	0	0.0 – 70.8
Phase 2: Combination Regimen - Cohort 3	9.5	1.2 – 30.4
Phase 2: Combination Regimen - Cohort 4	23.1	5.0 – 53.8

Number of Participants Experiencing Treatment-Emergent Adverse Events Secondary · Day 1 to 28 days after last dose of study treatment (up to a maximum of 125 weeks in phase 1 and a maximum of 92 weeks in phase 2)

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	5
Phase 1: Dose Escalation - 70 mg	4
Phase 1: Dose Escalation - 90 mg	10
Phase 2: Combination Regimen - Cohort 1	18
Phase 2: Combination Regimen - Cohort 2	3
Phase 2: Combination Regimen - Cohort 3	23
Phase 2: Combination Regimen - Cohort 4	18

Duration of Response (DR) Secondary · Up to approximately 10 months

DR was defined as the time in days from date of the first documentation of objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the first documentation of objective Progressive Disease (PD) or to death due to any cause in the absence of documented PD. DR was only calculated for the subgroup of participants who achieved a Best Overall Response of CR or PR and was presented for responses assessed by Investigator's assessment. Data is displayed for Phase 2 only, as no participants experienced an objective response (CR or PR) during Phase 1.

Group	Value	95% CI
Phase 2: Combination Regimen - Cohort 1	115	NA – NA
Phase 2: Combination Regimen - Cohort 3	329	NA – NA
Phase 2: Combination Regimen - Cohort 4	NA	230 – NA

Clinical Benefit Rate (CBR) Secondary · Up to approximately 10 months

Clinical benefit rate (CBR) was defined as the number of participants documented to have a confirmed Complete Response (CR), Partial Response (PR), or Stable Disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Participants who were not be able to be assessed for response were counted as non-responders.

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	1
Phase 1: Dose Escalation - 70 mg	2
Phase 1: Dose Escalation - 90 mg	2
Phase 2: Combination Regimen - Cohort 1	4
Phase 2: Combination Regimen - Cohort 2	0
Phase 2: Combination Regimen - Cohort 3	3
Phase 2: Combination Regimen - Cohort 4	5

Progression-Free Survival (PFS) Secondary · Randomization until progressive disease or death due to any cause (up to 42 months)

Progression-free survival (PFS) was defined as the time from date of first study treatment to first Progressive Disease (PD) or death due to any cause in the absence of documented PD per RECIST v1.1

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	3	1.88 – NA
Phase 1: Dose Escalation - 70 mg	NA	NA – NA
Phase 1: Dose Escalation - 90 mg	2	1.51 – 27.57
Phase 2: Combination Regimen - Cohort 1	3	2.01 – 5.86
Phase 2: Combination Regimen - Cohort 2	4	NA – NA
Phase 2: Combination Regimen - Cohort 3	2	1.94 – 14.57
Phase 2: Combination Regimen - Cohort 4	3	2.04 – 9.57

1-Year Survival Rate Secondary · 1 year

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	0.40	0.05 – 0.75
Phase 1: Dose Escalation - 70 mg	0.38	0.01 – 0.81
Phase 1: Dose Escalation - 90 mg	0.53	0.18 – 0.80
Phase 2: Combination Regimen - Cohort 1	0.72	0.41 – 0.89
Phase 2: Combination Regimen - Cohort 2	1.00	1.00 – 1.00
Phase 2: Combination Regimen - Cohort 3	0.52	0.31 – 0.70
Phase 2: Combination Regimen - Cohort 4	0.50	0.23 – 0.72

Overall Survival (OS) Secondary · From date of first study treatment until death due to any cause (up to 42 months)

OS was defined as the time from first dose of study treatment to the date of death due to any cause.

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	7	2.40 – 32.99
Phase 1: Dose Escalation - 70 mg	11	7.17 – NA
Phase 1: Dose Escalation - 90 mg	16	3.49 – 26.05
Phase 2: Combination Regimen - Cohort 1	NA	7.37 – NA
Phase 2: Combination Regimen - Cohort 2	NA	NA – NA
Phase 2: Combination Regimen - Cohort 3	15	7.73 – NA
Phase 2: Combination Regimen - Cohort 4	14	5.07 – 20.86

Concentration of Mocetinistat in Blood Plasma Secondary · Cycle 1 Day 1 pre-dose, 1, 3, and 7 hours post-dose, Cycle 1 Day 15 pre-dose and 1 hour post-dose, Cycle 2 Day 1 pre-dose and 1 hour post-dose, Cycle 3 Day 1 pre-dose and 1 hour post-dose and Cycle 7 Day 1 pre-dose (each cycle is 28 days)

Cycle 1: Day 1 - pre-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	NA	± NA
Phase 1: Mocetinostat 70 mg	0.91	± 83.20
Phase 1: Mocetinostat 90 mg	1.02	± 114.68
Phase 2: Mocetinostat 70 mg	39.65	± 175.97

Cycle 1: Day 1 - 1 hour post-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	19.85	± 441.16
Phase 1: Mocetinostat 70 mg	106.61	± 43.77
Phase 1: Mocetinostat 90 mg	92.56	± 143.96
Phase 2: Mocetinostat 70 mg	12.19	± 289.89

Cycle 1: Day 1 - 3 hours post-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	33.53	± 111.21
Phase 1: Mocetinostat 70 mg	61.63	± 24.78
Phase 1: Mocetinostat 90 mg	55.27	± 53.19

Cycle 1: Day 1 - 7 hours post-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	15.75	± 58.30
Phase 1: Mocetinostat 70 mg	20.92	± 27.20
Phase 1: Mocetinostat 90 mg	33.89	± 45.21

Cycle 1: Day 15 - pre-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	5.36	± NA
Phase 1: Mocetinostat 70 mg	0.98	± 95.06
Phase 1: Mocetinostat 90 mg	3.84	± 202.26
Phase 2: Mocetinostat 70 mg	1.92	± 127.96

Cycle 1: Day 15 - 1 hour post-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	102.67	± 7.17
Phase 1: Mocetinostat 70 mg	22.30	± 14646.88
Phase 1: Mocetinostat 90 mg	18.32	± 1297.79
Phase 2: Mocetinostat 70 mg	10.86	± 330.59

Cycle 2: Day 1 - pre-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	0.72	± NA
Phase 1: Mocetinostat 70 mg	0.85	± NA
Phase 1: Mocetinostat 90 mg	1.22	± 83.65
Phase 1: Mocetinostat 40 mg	NA	± NA
Phase 2: Mocetinostat 70 mg	1.16	± 91.63
Phase 2: Mocetinostat 50 mg	0.68	± NA

Cycle 2: Day 1 - 1 hour post-dose

Group	Value	95% CI
Phase 1: Mocetinostat 50 mg	75.11	± 25.53
Phase 1: Mocetinostat 70 mg	49.30	± 86.19
Phase 1: Mocetinostat 90 mg	2.45	± 83.60
Phase 1: Mocetinostat 40 mg	0.72	± NA
Phase 2: Mocetinostat 70 mg	14.65	± 396.22
Phase 2: Mocetinostat 50 mg	105.00	± NA

Concentration of Durvalumab in Blood Plasma Secondary · Cycle 1 Day 1 pre-dose + end of infusion, Cycle 1 Day 15 pre-mocetinostat dose, Cycle 2 Day 1 pre-dose, Cycle 3 Day 1 pre-dose, Cycle 4 Day 1 pre-dose + end of infusion, Cycle 7 Day 1 pre-dose + 90 days after participant's last dose (Up to max 133 weeks)

Plasma concentration of Durvalumab was evaluated. All participants received the same Durvalumab dose regardless of Mocetinistat dose group.

Cycle 1: Day 1 - pre-dose

Group	Value	95% CI
Durvalumab	259.18	± 334.86

Cycle 1: Day 1 - end of infusion

Group	Value	95% CI
Durvalumab	385779.56	± 36.49

Cycle 1: Day 15 - pre-Mocetinostat

Group	Value	95% CI
Durvalumab	102925.55	± 40.05

Cycle 2: Day 1 - pre-dose

Group	Value	95% CI
Durvalumab	44140.86	± 130.83

Cycle 3: Day 1 - pre-dose

Group	Value	95% CI
Durvalumab	72049.14	± 91.22

Cycle 4: Day 1 - pre-dose

Group	Value	95% CI
Durvalumab	101852.34	± 89.01

Cycle 4: Day 1 - end of infusion

Group	Value	95% CI
Durvalumab	365307.01	± 81.59

Cycle 7: Day 1 - pre-dose

Group	Value	95% CI
Durvalumab	130335.14	± 70.34

Number of Participants With the Presence of Anti-Drug Antibody (ADA) in the Blood Secondary · Up to approximately 10 months

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	0
Phase 1: Dose Escalation - 70 mg	0
Phase 1: Dose Escalation - 90 mg	1
Phase 2: Combination Regimen - Cohort 1	1
Phase 2: Combination Regimen - Cohort 2	1
Phase 2: Combination Regimen - Cohort 3	1
Phase 2: Combination Regimen - Cohort 4	0

Number of Participants With Tumor Expression of Programmed Cell Death Ligand 1 (PD-L1) at Baseline Secondary · Baseline

No/Low PD-L1 Expression

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	0
Phase 1: Dose Escalation - 70 mg	0
Phase 1: Dose Escalation - 90 mg	0
Phase 2: Combination Regimen - Cohort 1	17
Phase 2: Combination Regimen - Cohort 2	0
Phase 2: Combination Regimen - Cohort 3	6
Phase 2: Combination Regimen - Cohort 4	9

High PD-L1 Expression

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	0
Phase 1: Dose Escalation - 70 mg	0
Phase 1: Dose Escalation - 90 mg	1
Phase 2: Combination Regimen - Cohort 1	0
Phase 2: Combination Regimen - Cohort 2	3
Phase 2: Combination Regimen - Cohort 3	8
Phase 2: Combination Regimen - Cohort 4	1

Missing

Group	Value	95% CI
Phase 1: Dose Escalation - 50 mg	5
Phase 1: Dose Escalation - 70 mg	4
Phase 1: Dose Escalation - 90 mg	8
Phase 2: Combination Regimen - Cohort 1	1
Phase 2: Combination Regimen - Cohort 2	0
Phase 2: Combination Regimen - Cohort 3	9
Phase 2: Combination Regimen - Cohort 4	4

Adverse events — posted to ClinicalTrials.gov

Time frame: Adverse events (AEs) are reported from the first day of study treatment until at least 28 days after last dose of study drug, and until resolution or stabilization of acute AEs (up to 125 weeks in Phase 1 and 92 weeks in Phase 2.) Serious adverse events (SAEs) are reported from the time of informed consent until 90 days after the last administration of mocetinostat or durvalumab (up to 133 weeks in Phase 1 and 101 weeks in Phase 2.). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Phase 1: Dose Escalation - 50 mg

Serious: 4/5 (80%)

Deaths: 5/5

Phase 1: Dose Escalation - 70 mg

Serious: 1/4 (25%)

Deaths: 2/4

Phase 1: Dose Escalation - 90 mg

Serious: 4/11 (36%)

Deaths: 9/11

Phase 2: Combination Regimen - Cohort 1

Serious: 6/18 (33%)

Deaths: 5/18

Phase 2: Combination Regimen - Cohort 2

Serious: 2/3 (67%)

Deaths: 0/3

Phase 2: Combination Regimen - Cohort 3

Serious: 5/23 (22%)

Deaths: 14/23

Phase 2: Combination Regimen - Cohort 4

Serious: 11/19 (58%)

Deaths: 12/19

Serious adverse events (40 terms)

Reaction	System	Phase 1: Dose Escalation -…	Phase 1: Dose Escalation -…	Phase 1: Dose Escalation -…	Phase 2: Combination Regim…	Phase 2: Combination Regim…	Phase 2: Combination Regim…	Phase 2: Combination Regim…
Pneumonia	Infections and infestations	—	—	—	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—
Septic shock	Infections and infestations	—	—	—	—	—	—	—
Malignant neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—
Pericarditis	Cardiac disorders	—	—	—	—	—	—	—
Cardiac tamponade	Cardiac disorders	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Oesophagitis	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Axillary pain	General disorders	—	—	—	—	—	—	—
Mucosal inflammation	General disorders	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—	—	—	—
Bacterial infection	Infections and infestations	—	—	—	—	—	—	—
Clostridium difficile colitis	Infections and infestations	—	—	—	—	—	—	—
Gastroenteritis adenovirus	Infections and infestations	—	—	—	—	—	—	—
Herpes zoster	Infections and infestations	—	—	—	—	—	—	—
Pyelonephritis	Infections and infestations	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
Femur fracture	Injury, poisoning and procedural complications	—	—	—	—	—	—	—
Ejection fraction decreased	Investigations	—	—	—	—	—	—	—

Other adverse events (231 terms — click to expand)

Reaction	System	Phase 1: Dose Escalation -…	Phase 1: Dose Escalation -…	Phase 1: Dose Escalation -…	Phase 2: Combination Regim…	Phase 2: Combination Regim…	Phase 2: Combination Regim…	Phase 2: Combination Regim…
Fatigue	General disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—	—	—
Pain	General disorders	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Flank pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Dysuria	Renal and urinary disorders	—	—	—	—	—	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—	—	—
Pericarditis	Cardiac disorders	—	—	—	—	—	—	—
Dry eye	Eye disorders	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—
Non-cardiac chest pain	General disorders	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—

Most-reported serious reactions: Pneumonia, Pericardial effusion, Atrial fibrillation, Septic shock, Malignant neoplasm progression, Pericarditis, Cardiac tamponade, Colitis.

Data from ClinicalTrials.gov NCT02805660 adverse events section.

Sponsor's own description

Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. · · 2018 · cited 299× · PMID 29843754 · DOI 10.1186/s13046-018-0777-4
The timeline of epigenetic drug discovery: from reality to dreams.
Ganesan A, Arimondo PB, Rots MG, Jeronimo C, et al · · 2019 · cited 234× · PMID 31791394 · DOI 10.1186/s13148-019-0776-0
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z, Wu X. · · 2020 · cited 147× · PMID 32875727 · DOI 10.1002/cam4.3410
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0
Combining epigenetic and immune therapy to overcome cancer resistance.
Gomez S, Tabernacki T, Kobyra J, Roberts P, et al · · 2020 · cited 130× · PMID 31877341 · DOI 10.1016/j.semcancer.2019.12.019
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Mazzone R, Zwergel C, Mai A, Valente S. · · 2017 · cited 113× · PMID 28572863 · DOI 10.1186/s13148-017-0358-y

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other Mirati Therapeutics Inc. trials

Trials by the same sponsor.

NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT06875310 — A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan · Phase 3 · recruiting
NCT06801418 — Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets · Phase 1 · completed
NCT05853575 — Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) · Phase 2 · active not recruiting
NCT05840510 — Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02805660 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mirati Therapeutics Inc.
Last refreshed: 6 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02805660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing